New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - codeine phosphate hemihydrate 8mg equivalent to 5.92 mg codeine; paracetamol 500mg;   - tablet - active: codeine phosphate hemihydrate 8mg equivalent to 5.92 mg codeine paracetamol 500mg   excipient: maize starch potassium sorbate povidone purified talc starch stearic acid - for adults and children aged 12 years and above for effective, temporary relief of pain and discomfort associated with: · headache · migraine headache · tension headache · period pain · back pain · muscle pain · arthritis · toothache · dental procedures · neuralgia · cold and flu symptoms in adults only (18 years and older) · sore throat paracetamol + codeine tablets also help reduce fever. paracetamol + codeine is suitable for asthmatics sensitive to aspirin and nsaids.

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - codeine phosphate hemihydrate 8mg equivalent to 5.92 mg codeine;  ; paracetamol 500mg - tablet - 500mg/8mg - active: codeine phosphate hemihydrate 8mg equivalent to 5.92 mg codeine   paracetamol 500mg excipient: magnesium stearate maize starch povidone starch - indicated for the temporary relief of pain and discomfort associated with: · headache · migraine headache · backache · toothache/dental surgery · menstrual pain · muscular pain · neuralgia · cold and flu symptoms · sore throat · arthritis

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - codeine phosphate hemihydrate 8mg equivalent to 5.92 mg codeine;  ; paracetamol 500mg - tablet - 500mg/8mg - active: codeine phosphate hemihydrate 8mg equivalent to 5.92 mg codeine   paracetamol 500mg excipient: magnesium stearate maize starch povidone starch

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - codeine phosphate hemihydrate 8mg equivalent to 5.92 mg codeine; paracetamol 500mg - tablet - 500mg/8mg - active: codeine phosphate hemihydrate 8mg equivalent to 5.92 mg codeine paracetamol 500mg excipient: magnesium stearate maize starch povidone starch

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - codeine phosphate hemihydrate 8mg equivalent to 5.92 mg codeine; paracetamol 500mg;   - tablet - active: codeine phosphate hemihydrate 8mg equivalent to 5.92 mg codeine paracetamol 500mg   excipient: maize starch potassium sorbate povidone purified talc starch stearic acid

United States - English - NLM (National Library of Medicine)

lannett company, inc. - codeine sulfate (unii: 11qv9bs0cb) (codeine anhydrous - unii:ux6owy2v7j) - codeine sulfate 15 mg - codeine sulfate tablets are indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [ s ee warnings and precautions ( 5.1 ) ] , reserve codeine sulfate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated. have not been tolerated, or are not expected to be tolerated. - have not provided adequate analgesia, or are not expected to provide adequate analgesia. have not provided adequate analgesia, or are not expected to provide adequate analgesia. codeine sulfate tablets are contraindicated for: - all children younger than 12 years of age [see warnings and precautions ( 5.4 )] . - post-operative management in children younger than 18 years of age following tonsillect

United States - English - NLM (National Library of Medicine)

nexgen pharma, inc. - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), chlorpheniramine maleate (unii: v1q0o9oj9z) (chlorpheniramine - unii:3u6io1965u) - codeine phosphate 54.3 mg - codeine phosphate and chlorpheniramine maleate is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older. important limitations of use not indicated for pediatric patients under 18 years of age [see use in special population (8.4)] patients with known hypersensitivity to codeine, chlorpheniramine or any of the inactive ingredients of codeine phosphate and chlorpheniramine maleate. persons known to be hypersensitive to certain other opioids may exhibit cross-sensitivity to codeine. teratogenic effects pregnancy category c there are no adequate and well-controlled studies of codeine phosphate and chlorpheniramine maleate in pregnant women. reproductive toxicity studies have not been conducted with codeine phosphate and chlorpheniramine maleate; however, studies are available with individual active ingredients or related active ingredients. because animal reproduction studies are not always predictive of human response, co

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - codeine sulfate (unii: 11qv9bs0cb) (codeine - unii:q830pw7520) - codeine sulfate 60 mg - codeine sulfate is an opioid analgesic indicated for the relief of mild to moderately severe pain where the use of an opioid analgesic is appropriate. codeine sulfate is contraindicated in patients with known hypersensitivity to codeine or any components of the product. persons known to be hypersensitive to certain other opioids may exhibit cross-sensitivity to codeine. codeine sulfate is contraindicated in patients with respiratory depression in the absence of resuscitative equipment. codeine sulfate is contraindicated in patients with acute or severe bronchial asthma or hypercarbia. codeine sulfate is contraindicated in any patient who has or is suspected of having paralytic ileus. enter section text here codeine sulfate is an opioid agonist and is a schedule ii controlled substance. codeine sulfate can be abused and is subject to criminal diversion.  drug addiction is characterized by compulsive use, use for non-medical purposes, and continued use despite harm or risk of harm. drug addiction is

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 30 mg - tablet, uncoated - excipient ingredients: potassium sorbate; maize starch; povidone; purified talc; stearic acid; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; pregelatinised maize starch - paracetamol/codeine gh 500/30 is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - dihydrocodeine bitartrate (unii: 8lxs95bsa9) (dihydrocodeine - unii:n9i9hdb855), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - dihydrocodeine bitartrate 32 mg - acetaminophen, caffeine, and dihydrocodeine bitartrate tablets are indicated for the relief of moderate to moderately severe pain. this combination product is contraindicated in persons with hypersensitivity to dihydrocodeine, codeine, acetaminophen, caffeine, or any of the inactive components listed above, or any situation where opioids are contraindicated including significant respiratory depression (in unmonitored settings or in the absence of resuscitative equipment), acute or severe bronchial asthma or hypercapnia, and paralytic ileus. this combination product is subject to the provisions of the controlled substance act, and has been placed in schedule iii. dihydrocodeine can produce drug dependence of the codeine type and therefore has the potential of being abused. like other opioid analgesics, dihydrocodeine may produce subjective effects other than analgesia (e.g., euphoria, relaxation), which may contribute to abuse by some patients. psychological dependence, physical dependence, and tolerance may d